Double Ebitda from 2010 to 2024

002901 Stock   32.77  0.37  1.14%   
Double Medical's EBITDA is increasing over the years with stable fluctuation. EBITDA is expected to dwindle to about 268.8 M. From 2010 to 2024 Double Medical EBITDA quarterly data regression line had arithmetic mean of  434,171,054 and r-squared of  0.02. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
283 M
Current Value
268.8 M
Quarterly Volatility
176.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Double Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Double Medical's main balance sheet or income statement drivers, such as Interest Expense of 7.5 M, Other Operating Expenses of 17.8 M or Net Income Applicable To Common Shares of 443.1 M, as well as many indicators such as . Double financial statements analysis is a perfect complement when working with Double Medical Valuation or Volatility modules.
  
This module can also supplement various Double Medical Technical models . Check out the analysis of Double Medical Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Double Stock

Double Medical financial ratios help investors to determine whether Double Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Double with respect to the benefits of owning Double Medical security.